Gossamer Bio Inc reports results for the quarter ended in September 30 - Earnings Summary

Gossamer Bio

08/11/2024 04:45

* Gossamer Bio Inc  GOSS.OQ  reported a quarterly adjusted
loss
of 14 cents​​ per share for the quarter ended September 30,
higher than the same quarter last year, when the company
reported EPS of -21 cents.  The mean expectation of ten analysts
for the quarter was for a loss of 15 cents per share. Wall
Street expected results to range from -22 cents to -1 cents per
share.
    * Revenue was $9.48 million​; analysts expected $7.70
million. 
    * Gossamer Bio Inc's reported EPS for the quarter was a loss
of 14
cents​.
    * The company reported a quarterly loss of $30.8 million.
    * Gossamer Bio Inc shares had fallen by 10.1% this
quarter and
lost 2.8% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 22.2%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Gossamer Bio Inc
is 7.00 
This summary was machine generated from LSEG data November 8 at
04:45 a.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.15          -0.14          Beat
 Jun. 30 2024      0.23           0.22           Missed
 Mar. 31 2024      -0.19          -0.19          Met
 Dec. 31 2023      -0.21          -0.21          Met